RELATED CME CONTENT

Rheumatic Disease eJournal Club

Malignancies Associated With Tumor
Necrosis Factor Inhibitors in Registries
and Prospective Observational Studies—A Systematic Review and Meta-Analysis

Publication:
Mariette X, Matucci-Cerinic M, Pavelka K, et al. Ann Rheum Dis. 2011;70:1895-1904.

	How to Obtain AMA PRA Category 1 Credit™ Review the provided journal abstract and slides. Listen to the audio discussion. Complete the CME posttest (each question must be answered correctly). Login to your account. Complete the credit and evaluation form. Print your personalized CME certificate. Technical Requirements

Release Date:   November 10, 2011
Expiration Date:   November 10, 2012

Estimated Time of Completion:  30 minutes

Description
The purpose of this activity is to discuss a systematic review and meta-analysis of the risk of malignancy in patients with rheumatic disease who are treated with a tumor necrosis factor inhibitor (TNFi).

Learning Objectives

1. Outline the study design, evaluating the risk of malignancy in patients treated with a TNFi.
2. Identify the characteristics of the studies evaluated in the systematic review.
3. Describe the risk of malignancy based on evidence from registry data and observational studies.

Target Audience
This activity is directed to rheumatologists, primary care physicians, and other clinicians who treat patients with rheumatic diseases, such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), gout, systemic lupus erythematosus (SLE), and ANCA-associated vasculitis.

Accreditation
The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Cleveland Clinic Foundation Center for Continuing Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association Council on Continuing Medical Education for Category 2 credit.

Activity Director

Leonard H. Calabrese, DO
Professor of Medicine
R.J. Fasenmyer Chair of Clinical Immunology
Vice Chairman
Department of Rheumatic and Immunologic Diseases
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Cleveland Clinic
Cleveland, Ohio

Faculty

Paul Emery, MA, MD, FRCP
Arthritis Research Campaign Professor of Rheumatology
Head, Academic Unit of Musculoskeletal Disease
University of Leeds
Clinical Director in Rheumatology
Leeds Teaching Hospitals Trust
Leeds, United Kingdom

Disclosure

In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.

The following faculty have indicated that they may have relationships which, in the context of their presentations, could be perceived as a potential conflict of interest:

All other planners, CME staff, and content reviewers have no relevant financial relationships to disclose.

The Cleveland Clinic Foundation Center for Continuing Education
acknowledges an educational grant for support of this activity from Genentech, Inc.

This CME activity was produced by the Cleveland Clinic Center for Continuing Education
and
 

CME Disclaimer